EXEL Climbing Ahead of FDA Decision

NASDAQ:EXEL   Exelixis, Inc
$EXEL shares starting to break-out.FDA decision scheduled to Nov. 29. "optimists like cabozantinib's chances for approval" says Motley Fool. Looks like negative over-all market conditions weighing in on the stock move. Watch this one!


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.